CTRI/2020/03/023951
Not yet recruiting
Phase 4
A prospective, randomized, triple-blind comparative study of ropivacaine-dexmedetomidine versus ropivacaine alone in peribulbar blocks
Gayatri vidya parishad Institute of health care and medical technology0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Gayatri vidya parishad Institute of health care and medical technology
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria for our study consist of both male and female patients with an age range between 40 and 80 years and are of American Society of Anesthesiologists (ASA) physical status grades I and II attending our medical college hospital for elective cataract surgery.
Exclusion Criteria
- •The exclusion criteria for our study include patients with known allergy to study drugs, those refusing the regional block, those on anticoagulant therapy, high myopia (axial length of eyeball \> 28 mm), previous ophthalmic surgery such as buckling surgery, glaucoma, posterior staphyloma, ocular infection, orbital anomaly, mental retardation, uncontrolled hypertension \& diabetes mellitus, and chronic obstructive pulmonary disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Ropivacaine versus bupivacaine plus lidocaine in peribulbar blocksHealth Condition 1: H251- Age-related nuclear cataractHealth Condition 2: O- Medical and SurgicalCTRI/2021/08/035884Gayatri vidya parishad Institute of health care and medical technology
Completed
Not Applicable
A clinical study to assess the safety and effectiveness of collagen-containing test products in healthy adult Human subjectsCTRI/2022/11/047566Bright LifeCare Private Limited56
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-GBGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-DEGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageVaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).MedDRA version: 18.1Level: PTClassification code 10069613Term: Varicella immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10069628Term: Varicella immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10063315Term: Varicella zoster virus DNA test positiveSystem Organ Class: 100000004848MedDRA version: 18.0Level: LLTClassification code 10046983Term: Varicella zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: PTClassification code 10046980Term: VaricellaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: LLTClassification code 10050331Term: Varicella-like rashSystem Organ Class: 100000004858MedDRA version: 18.0Level: LLTClassification code 10063144Term: Varicella zoster virus serology positiveSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-003535-30-EEGlaxoSmithKline Biologicals1,220